Summary Among gastric cancer patients, the Rhesus D-negative phenotype correlated with increased tumour recurrence [all patients, n= 83, P = 0.026; curatively (RO) resected patients, n = 51, P = 0.093] and reduced overall survival time (all patients, log-rank P = 0.0028; RO patients, log-rank P= 0.0003) and was identified in multivariate analysis as the most important independent prognostic marker in the R0 patient group (relative risk 9.1, P= 0.0013).
Identification of high-risk cancer patients and the development of prognosis-oriented, multimodal therapy adapted to the individual patient is one of the main goals of current oncological research. Towards this end, much effort is currently being directed towards the identification of new, independent prognostic parameters often employing laborious molecular biological and immunohistological approaches. In gastric cancer, a variety of cell adhesion molecules, secreted products and gene-regulatory proteins have been identified as potential risk factors (Tahara, 1995) . Among the factors that are readily determined in tumour patients receiving surgical treatment are the blood group antigens. In contrast to extensive studies on the ABO system, the prognostic relevance of the Rhesus factor has only been sporadically investigated (Halvorsen, 1986; Cerny et al, 1987; Kvist et al, 1990 Kvist et al, , 1992 Bryne et al, 1991a, b; Raitanen and Tammela, 1993) and has not been reported for gastric cancer. The aim of the present study was to evaluate the prognostic impact of the Rhesus phenotype in gastric carcinoma patients. (Roder et al, 1993) . Lymphatic and blood vessel invasion and the presence of tumour cells in bone marrow, which are proposed as new prognostic factors (Maehara et al, 1995; Jauch et al, 1996) , were also considered. Data for these three parameters were not available for all patients.
PATIENTS AND METHODS
Prospective follow-up was routinely performed every 6 months and considered tumour recurrence and overall survival. In RO patients, local and distant tumour relapse were evaluated, while in R1 patients distant metastases only were considered. In patients with macroscopic residual tumour (R2) tumour recurrence was not evaluated. Overall survival data were available for all patients.
Statistical analyses were performed using the Fisher's exact probability test (two-tailed) (Kvist et al, 1990; Raitanen and Tammela, 1993; Slater et al, 1993) . No E-cadherin and CD44, the immunologically relevant HLA ABC and HLA DR antigens, the accessory molecules ICAM-1 and LFA-3 and the components of the uPA protease system by the primary tumour (data not shown). Analysis of tumour recurrence and overall survival revealed that the Rhesus D-negative phenotype was associated with poor outcome in both patient cohorts. In the total patient group, local or distant tumour relapse was evaluable in 56 patients (RO, 50 out of 51; R1, 6 out of 10). Tumour recurrence was more frequent in Rhesus D-negative patients (8 out of 9) than in Rhesus D-positive patients (21 out of 47; P = 0.026; median follow-up 12 months, range 1-82 months). A similar trend was observed in the RO group. Tumour recurrence was demonstrable in five out of six Rhesus D-negative patients, but only in 43% (19 out of 44) of the Rhesus D-positive patients (P = 0.093, median follow-up 24 months, range 1-82 months). Kaplan-Meier survival curves show that Rhesus D-negative patients had significantly shorter overall survival times than Rhesus D-positive patients in both the total (n = 83) and in the RO (n = 51) cohort (Figure) .
Multivariate analysis was performed to determine if the Rhesus D-negative phenotype is an independent predictor of poor prognosis. This analysis included all parameters listed in Table 1 univariately influencing survival of the patient cohorts at a significance level of P < 0.05 (Table 2 ). In the total patient collective, conventional clinicopathological parameters, i.e. residual tumour after surgical treatment, advanced depth of tumour invasion and the presence of lymph node and distant metastases at time of diagnosis, were found to be independent determinants of poor prognosis ( Table 2 ). The Rhesus factor was not an independent prognostic factor in the total patient cohort. In contrast, in the group of RO patients who are characterized by a more favourable tumour stage, the Rhesus D-negative phenotype was found to be a powerful independent predictor of poor prognosis (P=0.0013; relative risk 9.1), ranking before the positive nodal status and the performance of an extended operation (Table 2 ).
An association between Rhesus D-negative phenotype and tumour prognosis has also been observed in other tumours. In oral squamous cell carcinoma, Rhesus D-negative phenotype was identified as an independent parameter associated with tumour progression (Bryne et al, 199 la, b) . In contrast, in colorectal carcinoma Rhesus D-negative phenotype was associated with a favourable tumour stage (Halvorsen, 1986) and in urogenital carcinomas the Rhesus phenotype had no prognostic impact (Kvist et al, 1990 (Kvist et al, , 1992 Raitanen and Tammela, 1993) . Interestingly, in small-cell lung cancer, no association was observed between Rhesus phenotype and survival but an increased frequency of Rhesus D-negative individuals was seen, suggesting a predisposal towards this tumour (Cerny et al, 1987 (Cerny et al, ,-1992 .
The role of the Rhesus factor in tumour progression remains unclear. The function of Rhesus D itself, a molecule that has the structural characteristics of an ion transporter (Telen, 1995) , may be important in the maintenance of normal cell growth and differentiation. An alternative possibility is that the Rhesus D-negative phenotype is associated with the loss or alteration in one or more genes directly involved in tumour development. The Rhesus D gene is located on chromosome 1 between p34 and p36 (Cherif-Zahar, 1991), a region recently shown to be the location of a putative gastric carcinoma tumour-suppressor gene (Sano et al, 1991; Ezaki et al, 1996) . Inasmuch as the Rhesus D-negative phenotype is usually associated with a deletion of this gene (Hyland et al, 1994) , it is possible that this tumour-suppressor gene is also altered or deleted in some Rhesus D-negative individuals, a situation which could directly influence tumour growth and/or tumour progression.
Approximately 50% of curatively (RO) resected gastric cancer patients will die of tumour recurrence despite a favourable tumour stage. In the present study, the Rhesus D-negative phenotype has been detected as a new independent factor of poor prognosis in RO resected gastric cancer patients. This finding suggests that the routinely evaluated Rhesus phenotype may be an important marker for the selection of RO resected, high-risk cancer patients who should be considered in prognosis-associated multimodal therapy.
